Scinai Immunotherapeutics Ltd.
NNASDAQ:SCNIImportant Dates
Scinai Immunotherapeutics Ltd.'s next confirmed earnings release is scheduled for December 2, 2026.
| Earnings Date | 12/2/2026 |
Share Statistics
As of June 30, 2026, Scinai Immunotherapeutics Ltd. has 22.80B shares outstanding.
| Shares Outstanding | 22.80B |
Financial Position
As of June 30, 2026, Scinai Immunotherapeutics Ltd. maintains a current ratio of 1.56, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.56 |
| Quick Ratio | 1.47 |
| Debt / Equity | 30.51 |
Financial Efficiency
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 41.50 |
Stock Price Statistics
USDAs of the close on November 6, 2026, Scinai Immunotherapeutics Ltd.'s stock has declined approximately 95.84% over the past 52 weeks. The 50-day moving average sits at 1.28, while the 200-day moving average is 4.26.
| 52-Week Price Change | -95.84% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 4.26 |
Balance Sheet
USDAs of June 30, 2026, Scinai Immunotherapeutics Ltd. holds 2.65M in cash and equivalents against 3.58M in total debt, resulting in a net debt position of -2.37M. Total book value stands at 6.11M, with working capital of 1.26M providing operational flexibility.
| Cash & Cash Equivalents | 2.65M |
| Total Debt | 3.58M |
| Net Debt | -2.37M |
| Equity (Book Value) | 6.11M |
| Working Capital | 1.26M |
Cash Flow
USDThese figures cover the twelve months ended June 30, 2026.
| Capital Expenditures | -118,000.00 |
Stock Splits
Scinai Immunotherapeutics Ltd.'s most recent stock split took place on August 21, 2026 with a 10:1 split ratio.
| Last Split Date | 8/21/2026 |
| Split Ratio | 10:1 |